28 completed, 13 unknown, 11 terminated, 6 recruiting. 63 Phase 3, 18 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 63 | Completed 28, Unknown 13, Terminated 11, Recruiting 6, Withdrawn 3, Active not recruiting 1, Suspended 1 |
| Phase 2 | 18 | Completed 10, Terminated 3, Recruiting 2, Unknown 2, Withdrawn 1 |
Follow Paralysis: new trials by email Literature Review of Paralysis trials Research Report on Paralysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI) Galantamine Hydrobromide Extended Release - Spinal Cord Injury, Traumatic Spinal Cord Injury | Phase 2 / Phase 3 | Recruiting | Northwell Health | 60 | 2026-10-15 | 2026-11-04 |
| A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury NVG-291, Placebo - Chronic Spinal Cord Injury | Phase 3 | Recruiting | NervGen Pharma | 150 | 2026-09-28 | 2026-11-06 |
| A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy NIO752, Placebo - Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 300 | 2026-06-03 | 2026-10-15 |
| Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls. MELPIDA - Hereditary Spastic Paraplegia Type 50 | Phase 3 | Recruiting | Elpida Therapeutics SPC | 24 | 2026-04-01 | 2026-04-20 |
| Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients Steroids therapy, Placebo - Vestibular Schwannoma, Facial Nerve Paralysis | Phase 3 | Recruiting | Beijing Tiantan Hospital | 364 | 2025-10-09 | 2026-10-26 |
| Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy Botulinum Toxin A (Botox ), Pyloromyotomy - Esophageal Cancer Surgery, Esophagectomy | Phase 2 / Phase 3 | Recruiting | The Cleveland Clinic | 170 | 2024-12-03 | 2026-02-25 |
| Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis Oxymetazoline 0.1% (Pf) Oph Soln Ud, Preservative free lubricating drops - Blepharoptosis, Synkinesis | Phase 3 | Completed | Milton S. Hershey Medical Center | 36 | 2024-01-11 | 2026-03-09 |
| Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis Tradipitant - Idiopathic Gastroparesis, Diabetic Gastroparesis | Phase 3 | Completed | Vanda Pharmaceuticals | 17 | 2024-01-09 | 2026-10-19 |
| AMX0035 and Progressive Supranuclear Palsy AMX0035, Placebo - Progressive Supranuclear Palsy, PSP | Phase 2 / Phase 3 | Completed | Amylyx Pharmaceuticals Inc. | 139 | 2023-12-21 | 2026-04-30 |
| Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis Adezunap, Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Allograft Adipose Injectable for Vocal Fold Paralysis Renuva Allograft Adipose Matrix - Vocal Fold Palsy | Phase 3 | Unknown | University of Southern California | 50 | 2022-05-16 | 2023-02-06 |
| Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) Elamipretide, Placebo - Mitochondrial Myopathies, Mitochondrial Pathology | Phase 3 | Completed | Stealth BioTherapeutics Inc. | 102 | 2022-04-29 | 2025-10-24 |
| Stem Cells in Spinal Cord Injury Neuro-Cells - Spinal Cord Injuries, Acute Spinal Cord Injury | Phase 2 / Phase 3 | Unknown | Neuroplast | 16 | 2022-01-18 | 2023-09-29 |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 32 | 2021-11-02 | 2026-05-27 |
| PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis PET/CT Scan with 11C-ER176, Core biopsy of gastric muscle - Diabetes, Gastroparesis With Diabetes Mellitus | Phase 2 / Phase 3 | Completed | Mayo Clinic | 12 | 2021-05-10 | 2023-04-18 |
| A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients DaTSCAN™ Ioflupane (123I) Injection - Parkinsonian Syndrome, Parkinson Disease(PD) | Phase 3 | Completed | GE Healthcare | 172 | 2020-06-28 | 2023-10-16 |
| Diaphragmatic Paralysis Comparison Between Local Anesthetic Volumen Doses After Interscalene Block Interscalene brachial plexus block, Levobupivacaine Hydrochloride 2.5 MG/ML - Diaphragmatic Paralysis, Brachial Plexus Block | Phase 3 | Completed | Instituto de Investigación Sanitaria Aragón | 48 | 2020-02-11 | 2022-08-12 |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 40 | 2019-12-17 | 2026-05-22 |
| Interscalene Block and Dysfunction Diaphragmatic Ropivacaine 0.5% Injectable Solution, Ropivacaine 0.1% Injectable Solution - Diaphragmatic Paralysis | Phase 3 | Completed | University Hospital, Lille | 60 | 2019-10-29 | 2026-06-11 |
Showing 20 of 63. Sign in to see all of them.
Gastroparesis (20) · Quadriplegia (12) · Spinal Cord Injuries (12) · Diabetes Mellitus (10) · Paraplegia (10) · Hemiplegia (9) · Supranuclear Palsy, Progressive (9) · Vomiting (8) · Nausea (6) · Stroke (6) · Brain Injuries, Traumatic (4) · Muscle Spasticity (4) · Cerebral Palsy (3) · Facial Paralysis (3) · Multiple Sclerosis (3)
Neurologic Manifestations (63) · Pathological Conditions, Signs and Symptoms (63) · Signs and Symptoms (63) · Nervous System Diseases (42) · Central Nervous System Diseases (30) · Gastrointestinal Diseases (20) · Digestive System Diseases (19) · Brain Diseases (18) · Stomach Diseases (18) · Trauma, Nervous System (16) · Cranial Nerve Diseases (15) · Wounds and Injuries (15) · Metabolic Diseases (13) · Nutritional and Metabolic Diseases (13)
relamorelin (5) · Clinical Trials, Phase II as Topic (2) · Clinical Trials, Phase III as Topic (2) · Domperidone (2) · NG-Nitroarginine Methyl Ester (2) · Pyloromyotomy (2) · rimabotulinumtoxinB (2) · 4-Aminopyridine (1) · Acupuncture Therapy (1) · Adrenal Cortex Hormones (1) · Botulinum Toxins, Type A (1) · Electric Stimulation Therapy (1) · Electroacupuncture (1) · Fenofibrate (1) · Galantamine (1)
Allergan (5) · Assistance Publique - Hôpitaux de Paris (4) · Apurano Pharmaceuticals GmbH (2) · Assistance Publique Hopitaux De Marseille (2) · Burke Medical Research Institute (2) · Evoke Pharma (2) · Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC (2) · US Department of Veterans Affairs (2) · VA Office of Research and Development (2) · Vanda Pharmaceuticals (2) · ACADIA Pharmaceuticals Inc. (1) · Allegiance Health (1) · Allon Therapeutics (1) · Amylyx Pharmaceuticals Inc. (1) · Beijing Tiantan Hospital (1)
United States (35) · France (15) · Germany (13) · Spain (10) · United Kingdom (9) · Canada (8) · Australia (7) · Hungary (7) · Poland (7) · Belgium (6) · South Korea (6) · Bulgaria (5) · Denmark (5) · Israel (5) · Italy (5)
Harvy Schneier (2) · Joseph T Hull, PhD (2) · Adam Boxer, M.D., PhD. (1) · Andrea L Behrman, PhD (1) · Antonio Oliviero, MD (1) · Arthur Prochazka (1) · Catherine Geindre (1) · Charles Burgar, MD (1)
PMID 10946168, PMID 17385265, PMID 17965289, PMID 19029129, PMID 19618698, PMID 19651280, PMID 19771175, PMID 20012982, PMID 21372246, PMID 21386111, PMID 21674393, PMID 21762873, PMID 21829612, PMID 21872708, PMID 23700789, PMID 24873720, PMID 28436538, PMID 28726270, PMID 30166290, PMID 32250331, PMID 32773628, PMID 33874993, PMID 34289275, PMID 34934801, PMID 37924856, PMID 38237696, PMID 38825840, PMID 40148033, PMID 40773211, PMID 41195694, PMID 41286676, PMID 41491634, PMID 42244823
2017 (4), 2019 (2), 2008 (1), 2016 (1)